Options for corrections of the post-covid syndrome in routine clinical practice
Post updated: July 19
The present review article gives the results of source analysis regarding recommendations to detect, diagnose and treat the patients having post-COVID syndrome.
NICE (the National Institute for Clinical Excellence, 2020) Guideline defines post-COVID syndrome as features and symptoms which develop either during or after infection corresponding to COVID-19. The products influencing endothelium and CNS play an important role in treating post-COVID syndrome.
The following products of the company Nikopharm are available in the Ukrainian market: Nikomex (ethylmethylhydroxylpyridine succinate), Mildrocard (meldonium) and Pharmaxon (cyticoline); their clinical characteristics may help in routine clinical practice in order to ease the post-COVID syndrome caused by increased activity of the sympathetic nervous system and endothelial dysfunction: fatigue, tachycardia, asthenia, cognitive and psycho-emotional disorders, insomnia etc.
See the full text below.